biolitec AG
biolitec AG: Downstream Merger with Relocation to Austria in planning
biolitec AG / Key word(s): Strategic Company Decision 27.03.2012 15:26 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG: Downstream Merger with Relocation to Austria in planning Jena, March 27, 2012 - Jena-based biolitec AG, listed in Prime Standard segment of Frankfurt Stock Exchange (ISIN DE0005213409), wants to transfer its company domicile to Austria. To combine the relocation to Vienna with the already announced transfer to Entry Standard segment, major shareholder BioMed Technology Investment Holding has announced to vote for a downstream merger into biolitec AG's Austrian subsidiary at the occasion of the next general assembly of biolitec AG. Biomed Technology Investment Holding owns slightly over 75% of biolitec AG's shares, following the recent completion of a share buy back program. Therefore, the acceptance of a respective decision proposal is guaranteed. The relocation to Austria and the concomitant downstream merger to Entry Standard will allow biolitec AG to take advantage of tax optimization options, e.g. the use of Austria's favourable group taxation rules, and also bring biolitec AG closer to the growing future markets in Eastern Europe and Russia. In the course of the merger to the new value in Entry Standard, biolitec shares will be exchanged into new shares to maintain continuous trading for the shareholders in the quality segment Entry Standard of the Frankfurt Stock Exchange. The listing in Entry Standard of Frankfurt Stock Exchange is less demanding from a regulatory effort and thus saves cost for the company. In the merging of biolitec AG into the new Entry Standard-value, shares can customarily be traded continuously without retardation. As this process has some incalculable elements, we precautionary want to inform the shareholders that it is possible that a suspension of the trading of biolitec shares is a possibility. In the shareholders interest, biolitec will however endeavour to keep this suspension period as short as possible. 27.03.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Germany Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found